Traders Buy Regeneron Pharmaceuticals (REGN) on Weakness After Insider Selling

Traders bought shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on weakness during trading hours on Tuesday following insider selling activity. $140.79 million flowed into the stock on the tick-up and $117.65 million flowed out of the stock on the tick-down, for a money net flow of $23.14 million into the stock. Of all equities tracked, Regeneron Pharmaceuticals had the 20th highest net in-flow for the day. Regeneron Pharmaceuticals traded down ($18.10) for the day and closed at $324.57Specifically, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The sale was disclosed in a filing with the SEC, which is available through this link. 10.80% of the stock is owned by corporate insiders.

Several equities analysts recently commented on REGN shares. BidaskClub upgraded Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, January 26th. BMO Capital Markets set a $444.00 target price on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, November 27th. Citigroup lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $480.00 to $380.00 in a research note on Friday, December 1st. Robert W. Baird upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Friday, November 3rd. Finally, Argus dropped their target price on Regeneron Pharmaceuticals from $540.00 to $470.00 and set a “buy” rating for the company in a research note on Thursday, December 28th. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $463.19.

The stock has a market cap of $35,530.00, a P/E ratio of 32.04, a P/E/G ratio of 1.39 and a beta of 1.47. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.18 by $1.05. The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The firm’s revenue was up 28.9% on a year-over-year basis. During the same period in the prior year, the firm posted $3.04 earnings per share. research analysts predict that Regeneron Pharmaceuticals Inc will post 14.13 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC boosted its holdings in Regeneron Pharmaceuticals by 495.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 307 shares during the last quarter. Advisory Services Network LLC lifted its holdings in Regeneron Pharmaceuticals by 147.0% during the 4th quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 266 shares during the last quarter. Vident Investment Advisory LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $200,000. Mackenzie Financial Corp bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $204,000. Finally, Virtu KCG Holdings LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $206,000. 65.89% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Traders Buy Regeneron Pharmaceuticals (REGN) on Weakness After Insider Selling” was posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/02/15/traders-buy-regeneron-pharmaceuticals-regn-on-weakness-after-insider-selling.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply